Alkem launches FDC of Dapagliflozin, Sitagliptin and Metformin for adults with Type 2 diabetes in India

07 Oct 2022 Evaluate

Alkem Laboratories has launched for the first time in India, triple drug fixed dose combination (FDC) of Dapagliflozin, Sitagliptin and Metformin under the brand name of Dapanorm Trio at an affordable price for adults with Type 2 Diabetes in India.

Alkem's Dapanorm Trio will have a significant role in reducing HbA1c in uncontrolled type 2 diabetic patients & will help to improve patient compliance by reducing pill burden as well as medical bill burden. It will help the doctors to achieve good glycemic control in their patients. Dapanorm Trio has additional advantages like the lowest risk of hypoglycemia, better pancreatic beta cell protection, cardiac and renal benefits with better tolerability among elderly diabetic patients.

Alkem Laboratories is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical Ingredients (APIs) and nutraceuticals, which it markets in India and International markets.

Alkem Laboratories Share Price

5468.00 -31.75 (-0.58%)
30-Dec-2025 11:06 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.95
Dr. Reddys Lab 1266.60
Cipla 1486.85
Zydus Lifesciences 903.10
Lupin 2082.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×